Laurie Barclay, MD Sept. 30, 2002
Azithromycin improved pulmonary function in patients with cystic fibrosis (CF), according to results of a randomized trial reported in the Sept. 28 issue of The Lancet, suggesting that its use may be justified in patients refractory to conventional treatment.
“A four to six month trial of azithromycin is safe, comparatively inexpensive, and could greatly benefit the lung function of patients who do not respond adequately to conventional treatment for CF,” senior author Mark Rosenthal, FRCPCH, from Royal Brompton Hospital in London, U.K., says in a news release. “The mechanism of benefit remains unknown.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!